Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors are excluded~3. Subject should be able to start treatment no later than 12 weeks post-surgery~4. Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of signing the informed consent form (ICF)~5. ECOG/WHO Performance Status (PS) 0-1~6. Females of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy \[the surgical removal of the uterus\] or bilateral oophorectomy \[the surgical removal of both ovaries\] or (2) has not been naturally postmenopausal for at least 24 consecutive months \[i.e., has had menses at any time during the preceding 24 consecutive months\]) must:~   * Agree to the use of two physician-approved contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study IP; and for 3months following the last dose of IP~  * Has negative serum pregnancy test (β-hCG) result at screening~7. Male subjects:~   • Must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following IP discontinuation, even if he has undergone a successful vasectomy~8. Understand and voluntarily sign an ICF prior to any study related assessments or procedures being conducted~9. Be able to adhere to the study visit schedule and other protocol requirements~10. Acceptable hematology parameters defined as:~    * Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L~   * Platelet count ≥ 100 x 10⁹/L~   * Haemoglobin ≥ 5.6 mmol/L~11. Acceptable liver function defined as:~    * Serum bilirubin \< 1.5 x upper limit of normal (ULN)~   * ASAT/ALAT \< 2.5 x ULN~12. Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (e.g., using the Cockroft-Gault formula)~Exclusion Criteria:~1. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma~2. Presence of or history of metastatic or locally recurrent pancreatic adenocarcinoma~3. Other malignancies, except adequately treated basal carcinoma or squamous cell carcinoma of the skin or in situ cervix carcinoma or incidental prostate cancer (T1a, Gleason score ≤ 6, PSA \< 0.5 ng/ml), or any other tumor with a DSF survival of ≥ 5 years~4. History of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by chemotherapy treatment or which could not be controlled; including, but not restricted to:~   * Active infection requiring antibiotics within 2 weeks before the study inclusion~  * Concurrent congestive heart failure NYHA class III - IV~  * Unstable angina pectoris, or myocardial infarction within 6 months and/or prior poorly controlled hypertension~  * History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies~  * Concomitant use of immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications~5. Known or suspected allergy to the investigational agents or any agents given in association with this trial~6. Any psychological, familial, sociological, or geographical condition which does not permit protocol compliance and medical follow-up~7. Enrollment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures~8. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~9. Any condition that confounds the ability to interpret data from the study~10. Unwillingness or inability to comply with study procedures~11. Current use of anticoagulation therapy such as heparins both unfractionated and low molecular weighted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T-ChOS + Gemcitabine + Capecitabine (Type: EXPERIMENTAL): T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks.
- Placebo + Gemcitabine + Capecitabine (Type: PLACEBO_COMPARATOR): Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).